Corticotropin Releasing Hormone Is Correlated With Tumorigenesis of Gastric Cancer

REFERENCES

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang W, Zhang T, Ji J, Qian Q, Lu L, Fu H, Jin W, Cui D. Differential expression of phospholipase C epsilon 1 is associated with chronic atrophic gastritis and gastric cancer. PLoS ONE 2012;7:e47563.
   PubMedGoogle Scholar
• Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G, Dammacco F. H. pylori infection and gastric cancer: state of the art (Review). Int J Oncol 2013;42:5–18.
   PubMed Web of Science ®Google Scholar
• Ni J, Mei M, Sun L. Oxidative DNA damage and repair in chronic atrophic gastritis and gastric cancer. Hepatogastroenterology 2012;59:671–675.
   PubMed Web of Science ®Google Scholar
• Zhang C, Xu S, Xu D. Risk assessment of gastric cancer caused by Helicobacter pylori using CagA sequence markers. PLoS ONE 2012;7:e36844.
   PubMedGoogle Scholar
• Targosz A, Brzozowski T, Pierzchalski P, Szczyrk U, Ptak-Belowska A, Konturek S, Pawlik W. Helicobacter pylori promotes apoptosis, activates cyclooxygenase (COX)-2 and inhibits heat shock protein HSP70 in gastric cancer epithelial cells. Inflamm Res 2012;61:955–966.
   PubMed Web of Science ®Google Scholar
• Cheng H, Luo C, Wu X, Zhang Y, He Y, Wu Q, Xia Y, Zhang J. shRNA targeting PLC+Á inhibits bladder cancer cell growth in vitro and in vivo. Urology 2011;78:474.
   PubMedGoogle Scholar
• Bai Y, Edamatsu H, Maeda S, Saito H, Suzuki N, Satoh T, Kataoka T. Crucial role of phospholipase C in chemical carcinogen-induced skin tumor development. Cancer Res 2004;64: 8808–8810.
   PubMed Web of Science ®Google Scholar
• Taliouri E, Vrekoussis T, Vergetaki A, Agorastos T, Makrigiannakis A. Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand. Tumor Biol 2012;33:1–6.
   PubMedGoogle Scholar
• Arihara Z, Sakurai K, Osaki Y, Fukazawa H, Yamada S, Inoshita N, Murakami O, Ohba K, Takahashi K. ACTH response to desmopressin in a patient with acromegaly; expression of corticotropin-releasing factor, urocortins and vasopressin V1b receptor in GH-producing pituitary adenoma. Endocr J 2011;58:1029–1036.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Jones HP. Implications of corticotropin releasing factor in targeted anticancer therapy. J Pharm Pract 2010;23:86–90.
   Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2ΔΔCT method. Methods 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Ciocca D, Puy L, Fasoli L, Tello O, Aznar J, Gago F, Papa S, Sonego R. Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat 1990;15:175–184.
   PubMed Web of Science ®Google Scholar
• Miceli F, Ranelletti FO, Martinelli E, Petrillo M, Scambia G, Navarra P, Ferrandina G. Expression and subcellular localization of CRH and its receptors in human endometrial cancer. Mol Cell Endocrinol 2009;305:6–11.
   PubMed Web of Science ®Google Scholar
• Minas V, Rolaki A, Kalantaridou SN, Sidiropoulos J, Mitrou S, Petsas G, Jeschke U, Paraskevaidis EA, Fountzilas G, Chrousos GP, Pavlidis N, Makrigiannakis A. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer 2007;97:637–645.
   PubMed Web of Science ®Google Scholar
• Androulidaki A, Dermitzaki E, Venihaki M, Karagianni E, Rassouli O, Andreakou E, Stournaras C, Margioris A, Tsatsanis C. Corticotropin releasing factor promotes breast cancer cell motility and invasiveness. Mol Cancer 2009;8:30.
   PubMedGoogle Scholar
• Mumm JB, Oft M. Subversion and coercion: the art of redirecting tumor immune surveillance. Curr Top Microbiol Immunol 2011;344:25–39.
   PubMed Web of Science ®Google Scholar
• Kelly ME, Juern AM, Grossman WJ, Schauer DW, Drolet BA. Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol 2010;146:767–774.
   PubMed Web of Science ®Google Scholar
• Toulis KA, Goulis DG, Msaouel P, Koutsilieris M. Dexamethasone plus somatostatin-analog manipulation as bone metastasis microenvironment-targeting therapy for the treatment of castration-resistant prostate cancer: a meta-analysis of uncontrolled studies. Anticancer Res 2012;32:3283–3289.
   PubMed Web of Science ®Google Scholar
• Dietrich K, Schned A, Fortuny J, Heaney J, Marsit C, Kelsey KT, Karagas MR. Glucocorticoid therapy and risk of bladder cancer. Br J Cancer 2009;101:1316–1320.
   PubMed Web of Science ®Google Scholar
• Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001;1552:61–85.
   PubMed Web of Science ®Google Scholar
• Gang Y, Zhang X, He Y, Zheng J, Wu K, Ding J, Fan D. Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide. Biochem Cell Biol 2012;90:701–708.
   PubMed Web of Science ®Google Scholar
• Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbayo M, Segersten U, Malmström PU, Hartmann A, Palou J, Alvarez-Múgica M, Zieger K, Borre M, Ørntoft TF, Dyrskjøt L. Cathepsin E, Maspin, Plk1, and Survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol 2012;180: 1824–1834.
   PubMed Web of Science ®Google Scholar